Disadvantages of Pemigatinib

In clinical trials, serious adverse reactions in ≥2% of patients with cholangiocarcinoma treated with pemigatinib included abdominal pain, pyrexia, cholangitis, pleural effusion, acute kidney injury, infectious cholangitis, dysplasia, hypercalcemia, hyponatremia, small bowel obstruction, and urinary tract infection. Fatal adverse reactions include dysplasia, bile duct obstruction, cholangitis, sepsis, and pleural effusion. Adverse reactions were high in ≥20% of patients with myeloid/lymphoid neoplasms with FGFR1 rearrangements who received pemetinib. Phosphataemia, nail toxicity, alopecia, stomatitis, diarrhea, dry eye, fatigue, rash, abdominal pain, anemia, constipation, dry mouth, epistaxis, serous retinal detachment, limb pain, decreased appetite, dry skin, indigestion, back pain, nausea, blurred vision, peripheral edema, and dizziness.